“The third quarter of 2024 drew consistent attention to our pivotal-staged clinical asset, EB613, the first oral PTH(1-34) tablet treatment dedicated to post-menopausal women with high risk ...

Mohan, chairman of Dr. Mohan’s Diabetes Specialities Centre, Chennai. Semaglutide is available in oral (Rybelsus) and ...

The recent success of drug therapies such as semaglutide and tirzepatide has fueled obesity research ... The Company is also evaluating an oral tablet formulation of VK2735 (ClinicalTrials.gov ...

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...

US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...

Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates. Stock declines 11%.

Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for ...

The subcutaneous version of the medication tends to produce more pronounced side effects compared to its oral counterpart, necessitating thoughtful management strategies. Success with semaglutide ...

Semaglutide, the diabetes drug also known as Ozempic, has shown positive effects in treating patients with chronic kidney disease (CKD) and obesity, as revealed in an international study led by ...

Tablets may not be the hot new thing in 2024, but they're still excellent machines for streaming movies, playing games, or getting work done on the go. And while it seems like the best iPads ...

Modern advancements in medical science have provided new tools to help individuals overcome these obstacles, and Semaglutide is quickly becoming one of the most promising solutions in the field of ...